Key result
Drug-coated balloons showed no significant difference in major cardiovascular events compared to drug-eluting stents, but in-hospital major cardiovascular events was higher in large vessels >3 mm and in-stent thrombosis.
Why the study?
Does the use of drug-coated balloons during primary percutaneous coronary intervention reduce major adverse cardiac events in STEMI patients compared to drug-eluting stents?
Cohort (n=256)
No
Does the use of drug-coated balloons during primary percutaneous coronary intervention reduce major adverse cardiac events in STEMI patients compared to drug-eluting stents?
Drug-coated balloons appear non-inferior to drug-eluting stents for primary PCI in STEMI patients, but should be used with caution in large vessels and in-stent thrombosis.
Answers are grounded in this paper and cite their sources.
Supports non-inferiority of drug-coated balloons in STEMI PCI; hypothesis-generating and requires randomized confirmation before practice change.
OBJECTIVE: ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality worldwide. Current guidelines recommend primary percutaneous coronary intervention (PPCI) using drug-eluting stents as the standard management for these patients. Stent-free percutaneous coronary intervention (PCI) using drug-coated balloons (DCB) has been suggested as a novel approach to avoid stent-related complications. This study aimed to assess the efficacy and safety of using DCB in STEMI patients. METHOD: We compared STEMI patients who presented during the period between 2019 and 2023 and underwent primary PCI using DCB to those treated with drug-eluting stents (DES) in terms of in-hospital and six-month major adverse cardiac events (MACE). RESULTS: A total of 128 STEMI patients who underwent primary PCI using DCB were compared to 128 matched patients managed using DES. Small-vessel culprit lesions (< 3 mm) and distal lesions were significantly more frequent in the DCB group compared to the DES group. DCBs were used in major epicardial vessels in around 55% of patients and in side branches in almost 45% of cases. Regarding MACE, either in-hospital or within six months, there was no significant difference between the two groups. Moreover, at six-month follow-up, MACE, reinfarction, and repeat revascularization were numerically lower but statistically non-significant in the DCB group. Subgroup analysis showed that in-hospital MACE and reinfarction rates were statistically significantly higher when DCBs were applied to large vessels (> 3 mm) and in cases of in-stent thrombosis (P = 0.014 and 0.001, respectively). CONCLUSION: Drug-coated balloons appear non-inferior to DES during primary PCI in terms of MACE, including mortality and reinfarction, even in major epicardial coronaries. However, it should be used cautiously in certain lesion subsets, especially large vessels (> 3 mm) and in-stent thrombosis.
No takes yet. Share an insight, caveat, or question.
Darwish et al. (2026) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=256). Drug-coated balloons vs. Drug-eluting stents was evaluated on In-hospital and six-month major adverse cardiac events (MACE). Drug-coated balloons showed no significant difference in major cardiovascular events compared to drug-eluting stents, but in-hospital major cardiovascular events was higher in large vessels >3 mm and in-stent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: